Compare MCFT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | RGNX |
|---|---|---|
| Founded | 1968 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.5M | 418.1M |
| IPO Year | 2015 | 2015 |
| Metric | MCFT | RGNX |
|---|---|---|
| Price | $27.68 | $10.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $24.25 | ★ $28.75 |
| AVG Volume (30 Days) | 114.7K | ★ 577.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $284,203,000.00 | $10,393,000.00 |
| Revenue This Year | $9.18 | $51.21 |
| Revenue Next Year | $8.23 | $19.08 |
| P/E Ratio | $67.16 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $16.46 | $7.35 |
| 52 Week High | $26.49 | $16.19 |
| Indicator | MCFT | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 76.85 | 66.86 |
| Support Level | $19.79 | $7.76 |
| Resistance Level | N/A | $12.05 |
| Average True Range (ATR) | 1.00 | 0.57 |
| MACD | 0.32 | 0.17 |
| Stochastic Oscillator | 86.16 | 85.95 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.